JPH0337525B2 - - Google Patents
Info
- Publication number
- JPH0337525B2 JPH0337525B2 JP57195192A JP19519282A JPH0337525B2 JP H0337525 B2 JPH0337525 B2 JP H0337525B2 JP 57195192 A JP57195192 A JP 57195192A JP 19519282 A JP19519282 A JP 19519282A JP H0337525 B2 JPH0337525 B2 JP H0337525B2
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- acylcarnitine
- improving agent
- treatment
- edema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 18
- 229960004203 carnitine Drugs 0.000 claims description 18
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims description 9
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229960001009 acetylcarnitine Drugs 0.000 claims description 7
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- NGHNCQYFTPFRAD-SECBINFHSA-N (R)-acetoacetylcarnitine Chemical compound CC(=O)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C NGHNCQYFTPFRAD-SECBINFHSA-N 0.000 claims description 3
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- UEFRDQSMQXDWTO-YGPZHTELSA-N (R)-3-hydroxybutyrylcarnitine Chemical compound CC(O)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UEFRDQSMQXDWTO-YGPZHTELSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000008320 venous blood flow Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 21
- 206010030113 Oedema Diseases 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010046996 Varicose vein Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 208000027185 varicose disease Diseases 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003752 saphenous vein Anatomy 0.000 description 3
- 230000009724 venous congestion Effects 0.000 description 3
- 241000208011 Digitalis Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000037997 venous disease Diseases 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- YTJVKNAUWVYVNR-LLVKDONJSA-N (3R)-3,7-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]heptanoate Chemical compound OCCCC(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O YTJVKNAUWVYVNR-LLVKDONJSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010067035 Fear of pregnancy Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000019267 mild heart failure Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT49655A/81 | 1981-11-06 | ||
| IT49655/81A IT1142934B (it) | 1981-11-06 | 1981-11-06 | Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5888312A JPS5888312A (ja) | 1983-05-26 |
| JPH0337525B2 true JPH0337525B2 (enExample) | 1991-06-05 |
Family
ID=11271255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57195192A Granted JPS5888312A (ja) | 1981-11-06 | 1982-11-05 | カルニチンまたは低級アシルカルニチンからなる静脈疾患治療剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4415589A (enExample) |
| JP (1) | JPS5888312A (enExample) |
| IT (1) | IT1142934B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH655005A5 (it) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
| IT1184655B (it) * | 1985-10-14 | 1987-10-28 | Sigma Tau Ind Farmaceuti | Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock |
| US5641764A (en) * | 1989-03-31 | 1997-06-24 | Peter Maccallum Institute | Halogenated DNA ligand radiosensitizers for cancer therapy |
| IT1231944B (it) * | 1989-05-05 | 1992-01-16 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina |
| IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
| DK0793962T3 (da) * | 1996-03-04 | 2000-05-22 | Sigma Tau Ind Farmaceuti | Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans |
| IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| RU2245145C1 (ru) * | 2003-10-01 | 2005-01-27 | Российский государственный медицинский университет | Средство нормализации агрегационных свойств тромбоцитов и эритроцитов и морфоденситометрических характеристик эритроцитов |
| EP2096103A4 (en) | 2006-11-09 | 2012-11-21 | Mitsubishi Rayon Co | PROCESS FOR PREPARING A BETAIN |
| JP2012508267A (ja) * | 2008-11-11 | 2012-04-05 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | セルライトの処置に有用な化合物 |
| EP2353596A1 (en) | 2010-02-02 | 2011-08-10 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency |
| KR101758949B1 (ko) * | 2010-04-09 | 2017-07-17 | 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. | 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903558C2 (de) * | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Verwendung von L-Carnitin |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
-
1981
- 1981-11-06 IT IT49655/81A patent/IT1142934B/it active
-
1982
- 1982-11-01 US US06/438,012 patent/US4415589A/en not_active Expired - Lifetime
- 1982-11-05 JP JP57195192A patent/JPS5888312A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT1142934B (it) | 1986-10-15 |
| JPS5888312A (ja) | 1983-05-26 |
| IT8149655A0 (it) | 1981-11-06 |
| US4415589A (en) | 1983-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Freis et al. | Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents | |
| Carliner et al. | Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia | |
| JPH0337525B2 (enExample) | ||
| US8343979B2 (en) | Use of alkanoyl L-carnitine for the treatment of erectile dysfunction | |
| TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
| Young et al. | Severe arteriospasm after use of ergotamine tartrate suppositories: report of a case | |
| Page et al. | The prolonged treatment of hypertension with guanethidine | |
| KR100244092B1 (ko) | L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법 | |
| Athanassiadis et al. | Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| MEILMAN | The management of hypertensive cardiovascular disease | |
| Seller | Idiopathic orthostatic hypotension: Report of successful treatment with a new form of therapy | |
| ES2203115T3 (es) | Composicion que comprende ketanserina y l-carnitina para el tratamiento del sindrome de dolor local cronico. | |
| Schneider et al. | Hypervitaminosis D | |
| JP5923044B2 (ja) | 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物 | |
| JPH02262519A (ja) | 糖尿病性神経障害治療剤 | |
| RU2294204C1 (ru) | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки | |
| US6897239B1 (en) | Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women | |
| Hodge | Guanoclor as an antihypertensive drug | |
| MILLER et al. | Oral bismuth therapy in dermatology | |
| Botha | A clinical trial of pempidine in the treatment of hypertension | |
| Folb | Drugs in Common Use | |
| CN101087602A (zh) | L－肉碱和葡萄糖治疗心血管疾病的应用 | |
| MXPA99011357A (en) | Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps | |
| JP2014172846A (ja) | がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤 |